Page 9 - Mark Mintun News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.

But the drug, an antibody that attacks the sticky protein amyloid, does not work as well in people with more advanced disease. But the drug, an antibody that attacks the sticky protein amyloid, does not work as well in people with more advanced disease.

WASHINGTON (AP) — Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday. Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease — after […]

Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.

In a phase 3 trial, the monoclonal antibody donanemab slowed clinical and functional decline by 35% for patients with early Alzheimer's disease. However, the drug was not without safety issues.